BIIB vs ALNY Stock Comparison: AI Score, Valuation, Performance and Upside
Biogen and Alnylam both operate in specialized biotechnology niches, with Biogen focused on neuroscience treatments including multiple sclerosis and Alzheimer's disease, while Alnylam pioneers RNA interference therapeutics targeting rare genetic diseases and other conditions through a differentiated technology platform.
Biogen offers exposure to an established neuroscience franchise navigating competitive pressure and Alzheimer's commercial execution, while Alnylam offers exposure to a pioneering RNAi technology platform with broad pipeline potential. Consider whether you prefer Biogen's established neuroscience franchise or Alnylam's platform technology growth story.
BIIB holds the edge across 3 of 5 key metrics in this comparison. BIIB leads on both 1-year return (+56.98%) and forward P/E quality (13.21x vs 19.55x for ALNY), a relatively favorable combination of momentum and valuation. On fundamentals, ALNY is growing revenue faster (66.90%), while BIIB maintains the higher operating margin (25.06%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for ALNY (+50.42%) than for BIIB (+8.11%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want exposure to an established neuroscience treatment franchise spanning multiple sclerosis and Alzheimer's disease
- Believe Alzheimer's disease treatment adoption will continue improving over time
- Value diversified pipeline exposure across multiple neurological and rare disease indications
- Are comfortable with competitive and biosimilar pressure on the legacy multiple sclerosis franchise
- Believe RNA interference therapeutics represent a differentiated, high-potential technology platform
- Value a broad pipeline across multiple rare genetic disease areas offering numerous approval catalysts
- Are comfortable with the inherently limited revenue potential of individual rare disease products
- See upside potential as the commercial product portfolio continues to grow and mature
| Metric | BIIB | ALNY |
|---|---|---|
| AI scorei | 29.0 | 53.4 |
| AI ranki | #2338 | #335 |
| Latest closei | $220.83 | $266.11 |
| 1M returni | +6.20% | +21.40% |
| 6M returni | +17.31% | -17.76% |
| 1Y returni | +56.98% | -41.13% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | BIIB | ALNY |
|---|---|---|
| 1Y ago | $15.62K (+56.2%) started 2025-09-08 | $5.85K (-41.5%) started 2025-09-08 |
| 5Y ago | $7.36K (-26.4%) started 2021-09-09 | $14.28K (+42.8%) started 2021-09-08 |
| 10Y ago | $7.46K (-25.4%) started 2016-09-09 | $36.2K (+262.0%) started 2016-09-08 |
Hypothetical — past performance does not guarantee future results.
| Metric | BIIB | ALNY |
|---|---|---|
| Market capi | $32.28B | $32.93B |
| Trailing P/Ei | 38.74 | 42.95 |
| Forward P/Ei | 13.21 | 19.55 |
| Price/Salesi | 1.99 | N/A |
| EV/Revenuei | 3.92 | 6.79 |
| Analyst targeti | $236.22 | $370.20 |
| Target upsidei | +8.11% | +50.42% |
| Metric | BIIB | ALNY |
|---|---|---|
| Revenue growthi | 3.40% | 66.90% |
| Earnings growthi | -84.80% | N/A |
| EPS growthi | -84.80% | N/A |
| FCF margini | +12.63% | +5.65% |
| Operating margini | 25.06% | 17.93% |
| Profit margini | 8.32% | 16.13% |
| ROIC proxyi | 4.58% | 96.56% |
| Return on equityi | 4.58% | 96.56% |
| Dividend yieldi | N/A | N/A |
| Betai | 0.16 | 0.28 |
| Debt/equityi | 44.33 | 220.62 |
| Current ratioi | 1.86 | 3.06 |
| Quick ratioi | 0.94 | 2.79 |
Over the past year, BIIB and ALNY have moved weakly in the same direction (correlation of 0.16), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | BIIB | ALNY |
|---|---|---|---|
| 1Y | Growthi | +56.23% | -41.52% |
| CAGRi | +56.36% | -41.58% | |
| Volatilityi | 35.08% | 47.04% | |
| Sharpe ratioi | 1.32 | -0.98 | |
| Sortino ratioi | 2.12 | -1.18 | |
| Max drawdowni | 14.34% | 58.17% | |
| Current drawdowni | 1.64% | 45.83% | |
| Avg drawdowni | 4.90% | 28.76% | |
| Ulcer Indexi | 5.93% | 32.88% | |
| Max daily dropi | 8.17% | 28.31% | |
| Max wkly dropi | 12.37% | 24.38% | |
| 5Y | Growthi | -26.43% | +42.83% |
| CAGRi | -5.96% | +7.39% | |
| Volatilityi | 34.61% | 50.86% | |
| Sharpe ratioi | -0.14 | 0.30 | |
| Sortino ratioi | -0.24 | 0.47 | |
| Max drawdowni | 64.35% | 58.17% | |
| Current drawdowni | 30.57% | 45.83% | |
| Avg drawdowni | 31.73% | 19.90% | |
| Ulcer Indexi | 35.93% | 24.12% | |
| Max daily dropi | 8.17% | 28.31% | |
| Max wkly dropi | 13.62% | 24.38% | |
| 10Y | Growthi | -25.42% | +261.96% |
| CAGRi | -2.89% | +13.73% | |
| Volatilityi | 41.37% | 54.31% | |
| Sharpe ratioi | 0.02 | 0.43 | |
| Sortino ratioi | 0.03 | 0.65 | |
| Max drawdowni | 72.66% | 59.78% | |
| Current drawdowni | 46.75% | 45.83% | |
| Avg drawdowni | 34.58% | 22.76% | |
| Ulcer Indexi | 39.10% | 27.64% | |
| Max daily dropi | 29.23% | 48.49% | |
| Max wkly dropi | 34.30% | 49.44% |
| Category | BIIB | ALNY |
|---|---|---|
| Company | Biogen Inc. | Alnylam Pharmaceuticals, Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Biotechnology |
| Core business | A biopharmaceutical company focused on neuroscience treatments, including multiple sclerosis and Alzheimer's disease therapies, alongside a broader pipeline spanning rare disease and other neurological conditions. | A biotechnology company pioneering RNA interference therapeutics, developing treatments that silence disease-causing genes, with an approved product portfolio and pipeline spanning rare genetic diseases and other conditions. |
| Investor focus | Alzheimer's disease treatment commercial adoption trends, multiple sclerosis franchise stability amid competitive pressure, and pipeline progress across other neuroscience indications. | RNAi platform pipeline breadth and clinical progress, commercial product portfolio revenue growth, and path toward sustained profitability as the pipeline matures. |
- Established position in neuroscience treatment provides deep physician relationships and disease-area expertise
- Alzheimer's disease treatment franchise offers exposure to a large, underserved patient population with significant unmet medical need
- Diversified neuroscience pipeline spans multiple sclerosis, Alzheimer's, and other neurological and rare disease indications
- Pioneering position in RNA interference therapeutics provides a differentiated technology platform with broad potential applications
- Growing portfolio of approved products for rare genetic diseases provides increasing commercial revenue
- Broad pipeline across multiple disease areas offers numerous potential future product approval catalysts
- Multiple sclerosis franchise faces ongoing competitive pressure and biosimilar competition affecting legacy product revenue
- Alzheimer's disease treatment commercial adoption has faced challenges related to reimbursement, administration complexity, and market uptake pace
- Pipeline execution across neuroscience indications carries substantial clinical trial and regulatory risk
- RNAi platform technology, while promising, still carries ongoing clinical and regulatory execution risk across pipeline programs
- Rare disease focus means individual product revenue potential is inherently limited by smaller patient population sizes
- Path to sustained overall company profitability depends on continued successful pipeline execution and commercial scaling
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.